---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-046247"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2024-04-11T23:59:59+00:00"
generated_at: "2026-06-04T00:10:13.218675+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics updates pipeline; CNTY-101 shows durable responses, no allo-rejection in Ph1

## Summary
- CNTY-101 (CD19 iNK) in Ph1 ELiPSE-1 shows favorable safety, 2 CRs including 6-month durable CR, no allo-rejection.
- Plan to initiate Ph1 CALiPSO-1 trial in SLE in H1 2024; initial data expected by YE 2024.
- Cash, cash equivalents, and investments of $261.8M at end of Q4 2023; runway into 2026.
- Platform includes Allo-Evasion edits enabling repeat dosing without lymphodepletion; advancing iNK and γδ iT cell programs.
- Additional ELiPSE-1 data expected mid-2024; pursuing additional autoimmune health authority filings in 2024.

## SEC filing metadata
- accession: 0001104659-24-046247
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2024-04-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465924046247/0001104659-24-046247-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465924046247/tm2411557d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-046247
- JSON: https://secwatch.observer/filing/0001104659-24-046247.json
- Plain text: https://secwatch.observer/filing/0001104659-24-046247.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.